We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current APTCF market cap is 8.23k. The company's latest EPS is USD 0.0185 and P/E is 1.08.
| Year End July 30 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 350k | 0 | 0 | 0 | 0 |
| Operating Income | -820k | -936k | -432k | -507k | -705k |
| Net Income | -745k | -333k | -451k | -1.83M | 759k |
| Year End July 30 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 184k | 167k | 20k | 897k | 636k |
| Total Liabilities | 1.08M | 1.08M | 1.4M | 2.96M | 1.49M |
| Total Equity | -896k | -914k | -1.38M | -2.06M | -851k |
| Year End July 30 2022 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -1.21M | -685k | -467k | -545k | -693k |
| Investing | N/A | -1,000 | N/A | -50k | -14k |
| Financing | 1.21M | 683k | 337k | 1.42M | 429k |
| Market Cap | 8.23k |
| Price to Earnings Ratio | 1.08 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 1.52 |
| Price to Book Ratio | -0.97 |
| Dividend Yield | - |
| Shares Outstanding | 41.13M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | 0.00% |
| 52 Week High | 0.0002 |
| 52 Week Low | 0.0002 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Advanced Proteome Therapeutics Corporation (CE) |
| Address |
104 – 8337 eastlake drive burnaby, british columbia V5A 4W2 |
| Website | https://www.advancedproteome.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
